541 research outputs found
The relevance of the evolution of experimental studies for the interpretation and evaluation of some trace physical evidence
In order for trace evidence to have a high evidential value, experimental studies which mimic the forensic reality are of fundamental importance. Such primary level experimentation is crucial to establish a coherent body of theory concerning the generation, transfer and persistence of different forms of trace physical evidence. We contend that the forensic context, at whatever scale, will be specific to each individual forensic case and this context in which a crime takes place will influence the properties of trace evidence. it will, therefore, be necessary in many forensic cases to undertake secondary level experimental studies that incorporate specific variables pertinent to a particular case and supplement the established theory presented in the published literature. Such studies enable a better understanding of the specific forensic context and thus allow More accurate collection, analysis and interpretation of the trace physical evidence to be achieved. This paper presents two cases where the findings of secondary level experimental studies undertaken to address specific issues particular to two forensic investigations proved to be important. Specific pre-, syn- and post-forensic event factors were incorporated into the experimental design and proved to be invaluable in the recovery, analysis and in achieving accurate interpretations of both soil evidence from footwear and glass trace evidence from a broken window.These Studies demonstrate that a fuller understanding of the specific context within which trace physical evidence is generated and subsequently collected, as well as an understanding of the behaviour of certain forms of trace physical evidence under specific conditions, can add evidentiary weight to the analysis and interpretation of that evidence and thus help a court with greater certainty where resources (time and cost) permit
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with Hepatitis B virus infection
CD4+ CD25+ regulatory T cells have been shown to maintain peripheral tolerance against self and foreign
antigens. In this study we analyzed the effect of circulating CD4+ CD25+ T cells on CD8+-T-cell responses of
patients with chronic and resolved hepatitis B virus (HBV) infection. We demonstrated that circulating CD4+
CD25+ T cells modulate the function and expansion of HBV-specific CD8+ cells ex vivo in all patients,
regardless of whether they have chronic or resolved HBV infection. The possible role of CD4+ CD25+ T cells
in the pathogenesis of chronic HBV infection is not supported by these data. However, these results might have
implications for optimizing future immunotherapeutic approaches to HBV treatment
Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment
Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes. To address this question, the frequency and function of liver-, lymph node-, and blood-derived hepatitis B virus (HBV)-specific CD8 T cells were analyzed in patients treated with lamivudine and undergoing liver transplantation. HBV-specific CD8 T cells, identified in portal lymph nodes, were able to expand in vitro after antigen-specific stimulation and displayed a heterogeneous profile of cytokine production. These findings suggest that the peripherally reconstituted HBV-specific CD8 T cells can originate from precursor cells within lymph nodes
Energy level displacement of the excited nl state of pionic hydrogen
The energy level displacements of the excited nl states of pionic hydrogen
and the contribution of the ns -> 1s transitions and the (pi^-p)_Coul -> 1s
transitions of the pi^-p pair, coupled by the attractive Coulomb field in the
S-wave state with a continuous energy spectrum, to the shift of the energy
level of the ground state of pionic hydrogen, caused by strong low-energy
interactions, are calculated within a quantum field theoretic, relativistic
covariant and model-independent approach developed in nucl-th/0306047.Comment: 18 pages, no figures, latex, text is revised, references are adde
Aggressive treatment aimed at raising high-density lipoprotein cholesterol in stable patients with angiographically evident coronary disease prevents stenosis progression and reduces cardiovascular events
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Background An ongoing need exists for safe and effective lipid-lowering therapies (LLTs) for patients unable to achieve desired lipid levels with current treatment options. Objective The objective of this study was to describe the safety profile of bempedoic acid, an oral, first-in-class, adenosine triphosphate (ATP)–citrate lyase inhibitor that significantly reduces low-density lipoprotein cholesterol (LDL-C) levels by 17.4%–28.5% vs placebo. Methods This was a pooled analysis of four phase 3, randomized (2:1), double-blind, placebo-controlled studies in patients with hypercholesterolemia who required additional LDL-C lowering, despite stable maximally-tolerated LLT. Patients received 180 mg of bempedoic acid (n = 2424) or placebo (n = 1197) once daily for 12 to 52 weeks. Assessments included treatment-emergent adverse events (TEAEs) and clinical laboratory tests. Results Of 3621 patients (the median drug exposure: 363 days), exposure-adjusted TEAE rates were 87.1/100 and 82.9/100 person-years (PY) for bempedoic acid and placebo, respectively. No single TEAE influenced the difference in rates. TEAEs leading to discontinuation occurred at rates of 13.4/100 and 8.9/100 PY for bempedoic acid vs placebo, with the most common cause being myalgia, which occurred less frequently with bempedoic acid vs placebo (1.5/100 vs 2.0/100 PY). Rates of myalgia and muscle weakness were comparable vs placebo. Bempedoic acid was associated with mild increases in blood urea nitrogen, creatinine, and uric acid and decreases in hemoglobin. These laboratory abnormalities were apparent by week 4, stable over time, and reversible after treatment cessation. Gout incidence was 1.6/100 vs 0.5/100 PY in the bempedoic acid vs placebo groups. New-onset diabetes/hyperglycemia occurred less frequently with bempedoic acid vs placebo (4.7/100 vs 6.4/100 PY). The safety profile was consistent across subgroups. Conclusions Bempedoic acid is generally safe and well tolerated among patients with hypercholesterolemia who require additional LLT
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
Objectives To investigate whether statins reduce all cause mortality and major coronary and cerebrovascular events in people without established cardiovascular disease but with cardiovascular risk factors, and whether these effects are similar in men and women, in young and older (>65 years) people, and in people with diabetes mellitus
Love and limblessness: male heterosexuality, disability, and the Great War
Tens of thousands of British men were permanently wounded as a result of war service. Their return home sparked debates about the wounded male body, female accountability for war-injuries, and the ideology, performance, and practice of masculinity. Other historians have shown how ‘broken heroes’ from the First World War were constituted into ‘men’ in four contexts: physical appearance, occupation, sport, and Britishness. This article explores a fifth dimension: sexuality. It explores debates about the need for war-disabled men to establish stable marital relationships and investigates some attempts to encourage this, including encouraging women to take the initiative in proposing marriage and the establishment of The League for the Marrying of Broken Heroes
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Background: Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.Methods: We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.Results: the trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. the rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. the rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes.Conclusions: in this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.).AstraZenecaNovartisMerckAbbottRocheSanofi-AventisMerck-Schering-PloughIsisDade BehringVascular BiogenicsPfizerMerck FrosstResverlogixDupontAegerionArisaphKowaGenentechMartekReliantGenzymeGlaxoSmithKlineBoehringer IngelheimDiaDexusMedlogixAntheraBristol-Myers SquibbVIA PharmaceuticalsInterleukin GeneticsKowa Research InstituteTakedaBG MedicineOxford BiosciencesHarvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USAHarvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02215 USAUniversidade Federal de São Paulo, São Paulo, BrazilMcGill Univ, Ctr Hlth, Montreal, PQ, CanadaCornell Univ, Weill Cornell Med Coll, New York, NY 10021 USAUniv Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, NetherlandsUniv Ulm, Med Ctr, Ulm, GermanyHosp Cordoba, Cordoba, ArgentinaCopenhagen Univ Hosp, Herlev Hosp, Herlev, DenmarkUniv Glasgow, Glasgow, Lanark, ScotlandSt Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc
- …